Employers

Securities law

Allogene Therapeutics Selects Standard Fludarabine and Cyclophosphamide Regimen for Lymphodepletion in ALPHA3 Study

Allogene Therapeutics, Inc. has announced the selection of standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for its ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL). This decision was made following a Grade 5 adverse event in the FC plus ALLO-647 arm that